Categories Earnings, Health Care
Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot
— Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.
— Total revenue climbed by 34% to $71.5 million versus $68.39 million expected.
— Ocaliva net sales jumped by 33% to $70.3 million from last year. US sales increased by 30% and ex-US sales climbed by 42%.
— Research and development expenses increased by 2% primarily due to increases in development program expenses relating to its lead candidate, obeticholic acid (OCA), for liver fibrosis due to nonalcoholic steatohepatitis (NASH) and costs associated with the submission of new drug application.
— The FDA has set a Prescription Drug User Fee Act target action date of June 26, 2020, for the completion of its review of its NDA seeking approval of obeticholic acid for liver fibrosis due to NASH. The NDA was first accepted by the FDA for live fibrosis due to NASH.
— Looking ahead into full-year 2020, adjusted operating expenses are expected to be $560-600 million. This reflects its investments to support the launch of OCA for liver fibrosis due to NASH, commercial efforts in primary biliary cholangitis, clinical development and pipeline programs and other operating activities.
— During the fourth quarter, the company completed enrollment of Reverse, its phase 3 study evaluating OCA for the treatment of compensated cirrhosis due to NASH.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to
Comments
Comments are closed.